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Abstract
Background: A low intake of Fermentable, Oligo-, Di-, Mono-saccharides and Polyols (FODMAPs) is effective in the
symptom control of irritable bowel syndrome (IBS) patients but may exert negative effects on the intestinal
microbiota. The microbial effects of increasing regular or non-FODMAP fibre sources are largely unknown.
Furthermore, it is not known if the baseline microbiota composition is associated with individual symptom control
during the consumption of different rye products in IBS patients. Our objective was to evaluate whether increased
consumption of low-FODMAP rye bread or regular rye bread for 4 weeks would alter the intestinal microbiota
composition of IBS patients following their habitual diet, and whether these changes associate to symptoms and/or
the baseline microbiota.
Methods: The study was conducted as a randomized double blind controlled cross-over study (n = 50). Microbiota
was analysed by 16S rRNA gene sequencing and associated with gastrointestinal symptoms. Both microbial
changes and their associations to symptoms were secondary outcomes.
Results: The consumption of the test breads did not alter microbiota diversity. Compared to baseline, consumption
of the low FODMAP rye bread decreased the abundance of Bacteroides, Flavonifractor, Holdemania, Parasutterella
and Klebsiella and showed a trend towards increased bifidobacteria, whereas the regular rye bread decreased the
abundance of Flavonifractor. When comparing between the two test breads, Klebsiella was decreased after low-
FODMAP rye bread intake. Patients whose symptoms decreased during the low-FODMAP rye bread displayed more
Blautia and less Barnesiella at baseline.
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Conclusions: Consumption of low-FODMAP rye bread had modest, potentially beneficial effects on patients’
microbiota while increasing their intake of fibre substantially. The baseline microbiota composition was associated
with the variable degrees of symptom relief experienced by the patients. Consumption of a low-FODMAP rye bread
might be one way to increase dietary fibre intake and improve the mild dysbiosis often observed among patients
with IBS.
Trial registration: ClinicalTrials.gov: NCT02161120. Retrospectively registered 11 June 2014.
Keywords: Intestinal microbiota, FODMAP, Irritable bowel syndrome, IBS, Rye, Diet, Bifidobacteria, Blautia,
Symptoms, Responder
Background
Irritable bowel syndrome (IBS) is the most common dis-
order diagnosed by gastroenterologists. On average, it af-
fects 11% of the adult population in the developed
countries [1]. Adoption of a low-FODMAP diet, i.e. a
dietary approach restricting intake of poorly absorbable,
fermentable carbohydrates, has achieved acceptance in
the treatment of IBS both among gastroenterologists
and dieticians [2] because its use significantly reduces
the symptoms of IBS [3].
One disadvantage linked with a low-FODMAP diet is its
potential negative effect on the intestinal microbiota.
Especially the reduction of beneficial bifidobacteria and
also the reduced relative abundance of Akkermansia muci-
niphila, Faecalibacterium prausnitzii and Lactobacillus as
well as an increased tendency towards dysbiosis have been
reported [4–7]. The clinical importance of these theoretic-
ally unfavourable microbiota alterations after adoption of
a low-FODMAP diet is not fully understood. Nonetheless,
it seems reasonable to postulate that sustaining a high
relative abundance of these beneficial microbes would be
advantageous also in IBS patients to prevent long-term
adverse effects on gut and systemic health.
Whole grains are considered as healthy foods, mainly
due to their high fibre content [8]. A high consumption
of rye has been associated with a reduced risk of death
in men [9]. By consuming rye, an individual increases
his/her intake of cereal fibre and this has been linked to
a lower risk of colorectal cancer and cardiovascular
disease [10, 11]. On the other hand, grains are often
considered as triggers of IBS symptoms, e.g. rye is high
in FODMAPs, thus limiting the consumption of rye
products by IBS patients [2].
We have previously shown that low-FODMAP rye is
better tolerated than the regular rye bread in IBS pa-
tients [12]. The high consumption of low-FODMAP rye
bread allowed IBS patients to increase their fibre intake
by 7 g/day without compromising the symptom control.
These findings and the lack of any prior studies on the
effect of rye on the microbiota of IBS patients prompted
us to investigate whether a substantial increase in the
consumption of rye bread would induce changes in the
microbiota of IBS patients who otherwise followed their
habitual diet, and whether these changes would differ
between a low-FODMAP rye bread and regular rye
bread. We have previously shown that the baseline intes-
tinal microbiota composition may be related to the host’s
physiological response to whole grains and other dietary
fibres [13]. In addition, recent studies in IBS patients
have provided evidence that the resident microbiota in-
fluences the efficacy of a low-FODMAP diet in symptom
control [6, 14, 15]. Here, we examined whether the
microbiota of patients with clear symptom resolution
following the intake of the low-FODMAP bread, or
those in whom symptoms worsened after consuming the
regular rye bread, differed from the other participants in
the trial. In summary, we compared the microbial effects
of low-FODMAP-rye bread and the regular rye bread in
a randomized, double-blinded, crossover study in patients
with IBS and correlated the microbiota profiles with IBS
symptoms, and searched for potential microbiota signa-
tures which would characterize those patients whose
symptom control was profoundly altered following the
intake of either of the rye breads.
Materials and methods
Subjects and study design
A total of 87 subjects with IBS were recruited into the
study with 14 withdrawing from the study prematurely.
Only those subjects for whom fecal samples were suc-
cessfully collected and analysed at all three time points
were utilized in this study (n = 50). The subjects, study
design, measurement of symptoms, measurement of co-
lonic fermentation (breath hydrogen test), withdrawals,
flow chart, diets and quality of breads have been
described in detail in the report of the study’s primary
outcomes [12]. In short, this study (ClinicalTrials.gov:
NCT02161120) was a randomised, double blind, 2 × 2
cross-over trial with a 1 week run-in period when partic-
ipants adhered to their habitual diet, followed by two
4-week treatment periods during which the patients con-
sumed either the low-FODMAP rye bread or a regular
rye bread, with a washout period of ≥4 weeks between
these two periods (Fig. 1). The study protocol was
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approved by the ethics committee of the Hospital Dis-
trict of Helsinki and Uusimaa and all participants gave
written consent. Changes in microbiota and their associ-
ations to symptoms as described in this report were
secondary outcomes of the clinical trial.
Study breads
The breads were developed and supplied by Fazer Bakeries
(Vantaa, Finland). The breads had a similar appearance,
taste and were packaged in identical transparent plastic
bags. The control bread was prepared using traditional rye
sourdough whereas the low-FODMAP rye bread was
prepared using a specific sourdough system which re-
sulted in a rye bread with a clearly reduced FODMAP
(fructan and mannitol) content (12). The low-FODMAP
rye bread contained FODMAPs 0.4 g/100 g whereas regu-
lar bread contained 1.4 g of FODMAP /100 g. The partici-
pants were requested to consume 7–8 slices of rye bread
per day depending on individual energy needs during the
2nd, 3rd and 4th week; this led to a difference of 2.1–2.4 g
in their intake of FODMAPs/day. During the first week of
the treatment periods, the targeted rye bread dose was
halved, i.e. 3.5–4 slices. Further details can be found in the
previous publication (12) and in Table 1.
Fecal samples and DNA extraction
Fecal samples were collected at home at baseline and on
the 2nd last day of each intervention arm. The samples
were immediately stored at −20 °C and transported to
the study centre for DNA extraction within 6months.
Bacterial DNA was extracted from approx. 125 mg of
fecal matter using the Repeated Bead Beating (RBB)
method [16] with the following modifications for auto-
mated DNA purification: After the beat beating steps,
400 μl of the cell lysate pooled from the two beat beating
rounds was purified with the RSC Blood DNA kit
AS1400 in a Promega Maxwell RCS instrument (Pro-
mega, Madison, WI, USA). DNA was quantified using
Quanti-iT™ Pico Green dsDNA Assay (Invitrogen, San
Diego, CA, USA).
Microbiota analysis
Sample preparation for Illumina MiSeq paired-end se-
quencing of the hypervariable V3-V4 regions of the 16S
rRNA gene was performed according to the protocol
recommended by Illumina with a few modifications as
previously described [17].
Sequencing data preprocessing, analysis and statistics
The pre-processing of the sequencing reads, their taxo-
nomic annotation and statistical analysis were performed in
R using the package mare (Microbiota Analysis in R Easily)
[18] as previously described [19] with the following modifi-
cations: Reads < 0.001% were removed as potentially
erroneous and taxonomic mapping was done using Silva
database, which was pre-filtered to include only gut-associ-
ated taxa. Samples with less than reads 3000 were
discarded. The microbiota differences between the inter-
vention and responder groups were analysed using general-
ized linear models with negative binomial distribution for
bacterial genera detected in > 10% of the samples. Two
models were fitted for each taxon: one with all data points
and one with only the data points with non-zero values.
The effect of variable read count was controlled by using
the read count as an offset in all statistical models. Age,
Fig. 1 Study design
Table 1 Nutritional composition of the breads. Reproduced
from [12] with Creative Commons Attribution permission
Low-FODMAP
rye bread */100 g
Regular rye
bread*/100 g
Energy, kJ (kcal) 1024 (245) 1033 (247)
Protein, g 9.2 9.3
Fat, g 1.3 1.2
Carbohydrates, g 43.6 44.0
Dietary Fibre, g 10.2 10.5
Sodium, g 0.4 0.4
Fructans, g 0.3 1.1
Mannitol, g 0.1 0.3
LMWDF, g 1.9 2.6
Insoluble HMWDF, g 5.9 5.4
Soluble HMWDF, g 2.5 2.4
Resistant starch, g 0.9 0.8
LMWDF Low Molecular Weight Dietary Fibre, HMWDF High Molecular Weight
Dietary Fibre
*) Participants were supplied with and instructed to consume 3.5–4 slices
(105–120 g) of each bread/day during the trial’s first week and 7–8 slices (210–
240 g) during weeks 2–4 of the study
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BMI and treatment order were used as confounders in all
models with subject as a random factor. Gender was not
associated to microbiota variation (permutational ANOVA
r = 1%, p > 0.5) and was not used as a confounder. All
p-values obtained from these models were adjusted for
multiple testing using the Benjamini-Hochberg method
and reported as P.adjust. In addition, the spread of the data
was checked manually for all significant taxa obtained from
the models to avoid reporting false positives. The
β-diversity was estimated using Bray-Curtis dissimilarity as
the distance measure and the contribution of different vari-
ables to microbiota variation was calculated using permuta-
tonal ANOVA (vegan’s adonis function). The function
“CorrelationMap” of the mare package was used to study
the associations between bacteria and IBS symptoms. In
the univariate data, a statistical difference was evaluated
using t-test for two groups, and with ANOVA in combin-
ation with Tukey’s post-hoc test. For all tests, p-values <
0.05 were considered as statistically signifigant.
Responder definition
We grouped the patients based on the change in their
IBS-SSS and abdominal pain scores during the bread in-
terventions. We focused on two responder groups, clas-
sified as follows: 1) A reduction in their IBS-SSS score
by at least 50 points, as defined by Francis et al. [20],
and/or symptoms of pain reduced by more than 10mm
in the VAS (mean of weekly measures) as compared to
baseline during the low-FODMAP bread, or alterna-
tively 2) an increase in their IBS-SSS score by at least
50 points and/or symptoms of pain increased by more
than 10 mm at VAS (mean of weekly measures) com-
pared to baseline during the regular rye bread. The
symptom data were missing from one patient for each




Table 1 depicts the nutritional composition of the breads
including their FODMAP content and Table 2 summa-
rizes the characteristics of the participants. Participant
flow is described in Additional file 1: Figure S1. These
patients can be classified as suffering from moderate IBS
(mean IBS-SSS 235), as defined by Francis et al. [20].
Dietary intakes
The patients’ dietary intake is reported in Table 3. The
mean intake of energy was 7981 kJ/day during baseline,
8171 kJ/day when they were eating the low-FODMAP
rye bread and 8155 kJ/day when consuming the regular
rye bread. There were no statistically significant differ-
ences in energy or macronutrient intake between the
two interventions. Fibre intake increased by 7 g/day dur-
ing the low-FODMAP rye bread period and by 8 g/day
during the regular rye bread period as compared to the
baseline period (P < 0.001 for both vs. baseline, p = 0.92
for between the test breads).
Community-level effects of the intervention on the
intestinal microbiota
Our intestinal microbiota analysis was based on 10,554–
66,363 (mean 35,757) high-quality MiSeq sequences per
sample, representing 357 operational taxonomic units
(OTUs) and 84 bacterial genera. The microbiota of the
subjects at baseline consisted of Actinobacteria (mean
5.3%), Bacteroidetes (7.8%), Firmicutes (86.3%), Proteo-
bacteria (0.3%) and Verrucomicrobia (0.3%). At the
genus level, the most abundant bacteria were Lachnos-
piraceae Incertae Sedis (mean relative abundance
20.1%), Bacteroides (12.6%), Faecalibacterium (9.9%),
Blautia (9.0%) and Subdoligranulum (7.8%).
We estimated the community dissimilarity (β-diver-
sity) by performing a principal coordinates analysis
(PCoA) using Bray-Curtis dissimilarity as the distance
measure. There was no significant separation or distinct
microbiota clustering attributable to the treatments or
time points (P > 0.05). Permutational multivariate ANOVA,
with Bray-Curtis dissimilarities, was used to assess the
proportion of variation in the microbiota composition at-
tributable to the time points (baseline, 1st and 2nd bread)
and the treatments (low-FODMAP rye bread and regular
rye bread). The time points and treatment order both ex-
plained only 1% of the microbial variation in these patients
(P > 0.5, Additional file 2: Figure S2), indicating minor
effects on the overall community structure. Similarly,
α-diversity and/or richness were not affected by the inter-
vention (P > 0.4 for all comparisons).
Identification of specific bacterial taxa affected by the
intervention
Next, we compared the relative abundance of bacterial
genera between the treatments and the baseline. When
comparing the two interventions, the abundance of
Klebsiella was lower on the low-FODMAP rye bread
period as compared to the regular rye bread (P.adjust =
0.048, fc = 14.8). This was the only statistical difference
Table 2 Baseline characteristics of the participants
Females, n (%) 47 (94)
Age (years), mean (range) 43.9 (21–64)
BMI (kg/m2), mean (range) 25.6 (21–64)
IBS symptom severity score, mean (SD; range) 235 (77;80–430)
IBS-M, mixed subgroup, n (%) 29 (62.5)
IBS-D, diarrhoeal subgroup, n (%)
IBS-U, unspecified subgroup, n (%)
18 (32.5)
3 (5)
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in bacterial taxa noted in the comparison between the
breads. Both breads induced modest, partly overlapping
effects on the microbiota. Altogether five bacterial taxa
differed between the low-FODMAP rye bread and baseline
(Fig. 2). During the low-FODMAP rye bread period, the
abundances of Bacteroides (P.adjust = 0.03, fold change
fc = 1.59), two Firmicute genera i.e. Flavonifractor
(Ruminococcaceae, P.adjust = 0.06, fc = 1.55) and Holde-
mania (Erysipelotrichaceae, P.adjust = 0.08, fc = 1.84),
and two Proteobacterial genera i.e. Klebsiella (Gamma-
proteobacteria, P.adjust = 0.05, fc = 136.14) and Para-
sutterella (Betaproteobacteria, P.adjust = 0.04, fc = 1.97)
were reduced as compared to baseline.
The only difference between the regular rye bread ver-
sus baseline samples was the reduction of Flavonifractor
(Ruminococcaceae) (P.adjust = 0.01, fc = 14.83). Although
not reaching significance after adjustment for multiple
comparisons, there was a tendency towards an increase in
the abundance of bifidobacteria during the low-FODMAP
rye bread period (P = 0.03, P.adjust = 0.22, fc = 1.42), paral-
leled with a weaker upward trend during the regular rye
bread period (P = 0.28, P.adjust = 0.70, fc = 1.20). The
interventions had no effects on other bacteria including
Faecalibacterium prausnitzii and Lactobacillus spp. that
have previously been associated with consumption of a
low-FODMAP diet.
Associations of the microbiota to IBS symptoms and to
the individual variation in bread intake-related symptom
control
Correlation analysis between the microbiota and IBS symp-
toms (IBS-SSS, visual analogue scale (VAS) assessments of
individual symptoms and H2 production) during the inter-
vention yielded only two significant associations: H2
production was positively associated with the abundance of
Anaerostipes (r = 0.31, P = 0.003), and a weak positive cor-
relation was observed between constipation and Clostridia
FamilyXIII Incertae Sedis (r = 0.17, P = 0.035). As both the
intestinal microbiota and the tolerance to FODMAPs
varied considerably among IBS patients, it was thought that
subgroup analyses could provide novel insights into the re-
lationship between the microbiota and symptoms. Hence,
we zoomed in on those patients who experienced the most
intense change in symptom control during the interven-
tions and asked if patients who enjoyed symptom relief (re-
sponders) after consumption of the low-FODMAP bread
had a different microbiota composition compared to the
rest, here classified as non-responders.
Based on the criteria described in the methods, we
identified 18 responders and 31 non-responders for the
low-FODMAP bread. The individual GI symptoms that
differed significantly between the groups were flatulence
(P = 0.004), dyspepsia (P = 0.005) and heartburn (P = 0.04);
these symptoms were all significantly decreased in the re-
sponders when they were consuming the low-FODMAP
bread (Additional file 3: Figure S3A-C). The amount of
breath hydrogen (H2) was also significantly elevated in the
non-responders (P = 0.01, Additional file 3: Figure S3D).
The dietary intakes did not differ between the responder
groups at baseline but during the low-FODMAP rye bread
period, the non-responders consumed significantly less
fibre (24.3 g vs. 30.1 g, P = 0.04). The responder status was
not affected by IBS-subgrouping (IBS-D, IBS-M or
IBS-U), gender or age.
Considering the overall microbiota, a higher fraction
of the variation was attributable to the low-FODMAP
bread-related responder status (2%, P = 0.003) than to
the intervention itself (1%, P = 0.3; Fig. 3). The microbial
α-diversity was not affected by the responder status. At
baseline, the amount of Blautia was increased in the
responders (P.adjust = 0.01, fc = 1.6) whereas those of
Barnesiella (Porphyromonadaceae, Bacteroidales) were
reduced in the responders (P.adjust = 0.03, fc = 0.22,
Fig. 4). Finally, as a reference, the microbiota between
the subjects whose symptoms were strongly triggered
after the intake of the regular rye bread versus
were compared to those without a major symptom
change. Here, we identified 22 responders and 28
non-responders, with no microbiota differences be-
tween the groups (for all taxa P.adjust > 0.05).








Energy, kJ/d 7981 (±1992) 8171 (±2081) 8155 (±2466) NS
Energy, kcal/d 1906 (±476) 1952 (±497) 1948 (±589) NS
Carbohydrates, g/d 189 (±60) 199 (±60) 202 (±71) NS
Protein, g/d 86 (±25) 86 (±25) 89 (±29) NS
Fat, g/d 79 (±25) 78 (±26) 76 (±29) NS
Total fibre, g/d 21 (±9) 28 (±9) 29 (±9) <0.00011
Results are given as mean (SD). *) Overall comparison between study periods using t-test analysis of variance. NS = No significant differences between any three
periods. 1) both breads vs. baseline
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Discussion
This is the first time that the effects of regular and
low-FODMAP rye bread on the intestinal microbiota of
IBS patients have been investigated. The comparison of
two active treatments is usually conceived as the key
analysis in a cross-over trial. However, we did not ob-
serve any differences between the breads in terms of the
microbiota, apart from a presumably anecdotal finding
on the difference abundance of Klebsiella. Instead, our
results indicate that both breads induced parallel but
non-identical changes in the microbiota as compared to
baseline, which is logical as the increase in the daily fibre
intake of 7–8 g/d is likely to be a stronger stimulus to
the microbiota compared to the about 1 g difference in
the fructan intakes between the two bread periods.
Compared to baseline, consumption of the low-FOD-
MAP rye bread led to detectable but a non-significant
increase of bifidobacteria as well as decreases in several
of the genera (Fig. 2) that can be considered as poten-
tially harmful for IBS patients (see below). Our findings
are promising since the reduction in the numbers of bifi-
dobacteria has been recognized as a dysbiotic finding in
IBS patients [21] and an adverse effect of the
low-FODMAP diet. These and our previous results [12]
indicate that low-FODMAP rye bread represents an in-





































































































































Fig. 2 Relative abundance (± standard error) of the bacterial genera that differed between the baseline and low-FODMAP rye bread intervention,
and abundance of bifidobacterial in all time points. Statistical significance between each treatment arm versus baseline was calculated with
negative binomial models in the mare R package and is indicated with an asterisk (adjusted p < 0.05)
Laatikainen et al. BMC Nutrition            (2019) 5:12 Page 6 of 11
Fig. 3 Principal coordinates analysis (PCoA) plot of genus-level data based on Bray-Curtis dissimilarity. Samples are colored according to
responder status, defined by lower scores of IBS-SSS and/or pain during the low FODMAP rye bread period compared to baseline. The symbols







































































Fig. 4 Relative abundance of bacterial genera that differed significantly between the responders and non-responders; responders were identified
by lower scores of IBS-SSS and/or pain during the low FODMAP rye bread period compared to baseline. The box extends from 25th percentile to
75th percentile, with a line at the median; the whiskers refer to the highest and lowest values. Abundances are plotted for baseline and for both
bread periods and those with a statistically significant (adjusted p < 0.05) difference are indicated with an asterisk
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symptoms more than the regular rye bread, substantially
increases fibre intake and x consequently results in ap-
parently beneficial microbial changes in the gut.
Our study adds to the previous evidence that the
addition or substitution of specific, high-fibre grains/ce-
reals while the individual continues with his/her other-
wise habitual diet does not alter the microbial diversity
or cause other community-wide microbiota effects [22–
25]. Instead, specific changes in individual bacterial taxa
were observed when comparing the baseline versus
post-intervention microbiota (Fig. 2). Recently, Swedish
researchers studied the effects of refined wheat, whole
grains wheat and rye in 70 healthy volunteers [23]. The
intestinal microbiota composition was not affected by
any of these grain products in that 6-week cross-over
study. Similarly, a parallel-arm intervention trial con-
ducted in Finnish metabolic syndrome patients consum-
ing a diet with high amounts of rye at baseline, did not
change the microbiota composition between the subjects
who consumed either white wheat or rye bread for 12
weeks [24]. In our study, the intake of rye and other
grains was relatively low in the habitual diet, and hence
the introduction of the study rye breads substantially
altered the intake of high fibre grains.
The low-FODMAP rye bread decreased the relative
amounts of Bacteroides, Flavonifractor, Holdemania,
Klebsiella and Parasutterella (Fig. 2) as compared to
baseline. Members of the genus Bacteroides are abun-
dant commensals but some species are also significant
clinical pathogens [26], therefore the abundance changes
of this group cannot be regarded as either beneficial or
detrimental for IBS patients. Inhabitants of Western
countries typically have a very high abundance of Bacter-
oides as compared to those living in Africa where the
diet is heavily plant-based and contains high amounts of
fibre [27]. In this trial, the amounts of Flavonifractor
were reduced during both intervention periods when
compared to baseline. This organism uses gamma-ami-
nobutyric acid (GABA) as a growth substrate, and hence
presumably reduces the amount of GABA in the gut
[28]. As GABA has multiple regulatory effects in the in-
testine including a reduction of both transit time and
pain [29], our finding that an increased intake of cereal
fiber leads to a reduction in the numbers of “GABA-eat-
ing” Flavonifractor in IBS patients is rather interesting.
Recently, elevated levels of Flavonifractor were found in
the rectal mucosa of autistic children with functional
gastrointestinal disorders, especially in those individuals
reporting abdominal pain [30]. While GABA was not
measured in that study, the amount of Flavonifractor
correlated linearly with the levels of serotonin in the tis-
sue biopsy specimens. Increased levels of Flavonifractor
have also been assayed in feces of depressed adults [31],
further strengthening the rationale for additional studies
to clarify the link between Flavonifractor, intestinal pain
and mood disorders. Furthermore, GABA analogs such
as gabapentin and pregabalin have been reported to re-
duce visceral hypersensitivity in preclinical models [32]
and pregabalin has shown promise in reducing abdom-
inal pain in a clinical trial with IBS-patients [33]. In
addition, an increased abundance of bifidobacteria, i.e.
as occurred during consumption of the low-FODMAP
rye bread, has been reported to associate with a reduced
level of abdominal pain in cross-sectional studies of IBS
patients [34–36]. Taken together, these findings suggest
that dietary modifications that decrease the abundance
of Flavonifractor and increase the abundance of bifido-
bacteria might reduce the abdominal pain or accelerated
transit time in IBS.
Similarly to Flavonifractor, Parasutterella, the most
abundant proteobacterium in autistic children [37], has
been associated with abdominal pain in autistic children
[30]. Klebsiella is an opportunistic pathogen that is a
common cause of urinary tract infections and capable of
acquiring resistance to antibiotics. Its abundance has
been claimed to be high in some IBS subjects [38].
Holdemania has been reported as a key member of
bacterial networks of pediatric IBS patients [39] and to
be enriched in gout patients as compared to healthy con-
trols [40]. While the clinical implications of our findings
of the low-FODMAP diet induced microbiota alterations
remain unclear, it is evident that any reduction in the
numbers of the above-mentioned bacteria are likely to
have beneficial rather than harmful effects in IBS patients.
Our results suggest that prebiotic oligosaccharides in
grains belonging to the FODMAP family, such as fruc-
tans, can be substituted with other grain-based prebiotic
factors to improve the abundance of bifidobacteria and
to reduce IBS symptoms [12]. Previous in vitro studies
have shown that arabinoxylan-fibre from rye stimulates
the growth of human bifidobacteria [41, 42]. A rando-
mised trial in healthy volunteers revealed that arabinoxy-
lan enriched rye/wheat products increased the fecal
butyrate concentration and tended to increase the abun-
dance of bifidobacteria [22]. However, more studies will
be needed to clarify the clinical significance of the in-
crease in the abundance of bifidobacteria in IBS patients.
In addition, it would be interesting to investigate the
effects of non-FODMAP fibre components, especially
arabinoxylan, on the production of short-chain fatty acids
and on host metabolomics. Ultimately, only prospective
long-term studies will demonstrate if the increase in the
abundance of bifidobacteria will translate into beneficial
clinical outcomes in IBS patients.
The stratification of the subjects according to their
response to the low-FODMAP bread intake based on
the IBS-SSS and pain scores revealed that those patients
who benefitted from the intake of low-FODMAP rye
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bread (responders) had a different microbiota composition
at baseline than those whose symptoms were not im-
proved (non-responders). In particular, Blautia, a bacterial
species that decreases intestinal gas by producing acetate
[42], was significantly more abundant in responders versus
non-responders (mean 19% vs 14%, respectively). Previ-
ously, Chumpitazi et al. have demonstrated that pediatric
IBS patients whose symptoms markedly improved while
adhering to a low-FODMAP diet had a different micro-
biota composition as compared to those who did not
exhibit any improvement [14, 15]. In addition, adult IBS
patient responders to low-FODMAP diet have been
previously discriminated from non-responders before
and after intervention based on their fecal bacterial
profiles [6]. In our study, the subjects benefitting from
the low-FODMAP rye bread had significantly more
Blautia at baseline, suggesting that the ability to re-
move hydrogen might be at least as important a deter-
minant of IBS symptom control than the generation of
intestinal gas. Blautia utilizes hydrogen and carbon
dioxide to form acetate [43] and since it is one of the
most dominant intestinal genera, it presumably exerts a
significant role in reducing the intestinal gas volume
and pressure. These data suggest that increasing the
abundance of Blautia might have potential as a new
therapeutic target in IBS. The other bacterium that dif-
fered in abundance between the responder groups was
Barnesiella, which was lower in responders. In a recent
meta-analysis, Barnesiella was shown to be more abun-
dant in control subjects as compared to those with
intestinal diseases [44]. We did not detect any bacteria
to be specifically associated with a worsening of IBS
symptoms following the intake of regular rye bread.
This may reflect the fact that many different bacteria
are involved in the fermentation of dietary fibre and
hence the main gas-producing bacteria that contribute
to the symptoms probably vary between different indi-
viduals and cannot be quantified with phylogenetic
microbiota analysis.
One limitation of our study is that we did not include
patients with constipation predominant-IBS (IBS-C), as
we wished to keep the patient cohort as homogenous as
possible. Therefore, the results are not directly transfer-
able to patients with IBS-C. There is no database in
Finland on the FODMAP content of foods, especially
data on fructans and polyols is lacking; thus we were
unable to calculate the total amount of FODMAPs
consumed during the periods. Some participants may
have either reduced or increased their intake of other
FODMAPs accidently or intentionally during the study
despite our instructions. It is noteworthy that the intake
of fibre increased substantially during both intervention
periods; and only a difference of 1 g was noted owing to
different fructan content of the breads. We did not
analyse markers of low-grade inflammation and intes-
tinal permeability but a recent study indicated that a
high intake of rye may reduce low-grade inflammation
[24]. The measurements of these markers might have
shed light on the clinical relevance of the observed
microbial changes. Two studies investigating the effects
of a low-FODMAP diet have shown that even although
some changes in the microbiota appear to be unfavour-
able, the overall effects of the low-FODMAP diet on
low-grade inflammation and immune activation seem to
be beneficial [7, 45]. Therefore, it is premature to con-
clude if the microbial changes observed in IBS or during
different dietary interventions will translate into clinic-
ally meaningful outcomes.
The strength of our study is its double-blinded setting,
which is not often possible in dietary interventions.
Furthermore, the observed beneficial effects in the
microbiota were achieved by consuming a staple food,
i.e. bread. People with IBS may find it easier to adhere to
food modification in the long-term in comparison with
consuming probiotic or other relatively expensive dietary
supplements that might also increase the abundance of
at least some bifidobacteria strains among people with
IBS [46].
Conclusions
In conclusion, our double-blind study demonstrated that
consumption of a high-fibre low-FODMAP rye bread
displayed the potential to support healthy microbiota.
This kind of low-FODMAP rye bread might be a prac-
tical means of improving long term overall gut health in
IBS patients. Our results also can act as a foundation for
further studies focusing on gut microbiota and individ-
ual responses to clarify the mechanisms underpinning
diet-induced gastrointestinal symptoms as well as target-
ing dietary therapy to those individuals in whom they
will exert the maximum clinical benefits.
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